One Day Advisor

Updated October 21, 2026 · Originally published July 2025 · Written by the One Day Advisor Editorial Team · Reviewed by Frank Yap, MBA. Prices and fund data are as of October 16–21, 2026 unless another date is shown. Figures marked “est.” are unconfirmed and should be checked on the issuer’s fund page. Quick Answer As of October 21, 2026, the lowest-cost gold ETFs are IAUM (0.09%) and GLDM (0.10%), IAU (0.25%) offers scale, and GLD (0.40%) is the most liquid. For silver, SLV (0.50%) is the liquid benchmark and SIVR (0.30%) is the cheaper hold. Gold is near $4,127 an ounce, about 23% below its January record, so miner and leveraged funds carry far more risk than bullion funds. Disclosure This article is educational and is not financial or investment advice. Some links to TradingView are affiliate links; we may earn a commission at no cost to ...

Medically & Financially Reviewed by: Dr. Frank Yap, MD, MBA | Written by: OneDayAdvisor Editorial Team | Last Updated: September 2026 Quick Answer Merck & Co. remains the world's top cancer drug company by 2025 oncology revenue (~$35.4 billion, driven overwhelmingly by Keytruda) , followed by Roche (~$29–30 billion), AstraZeneca ($25.6 billion), Johnson & Johnson ($25.4 billion), and Bristol Myers Squibb (~$25.0 billion). Global oncology drug spending topped an estimated $291 billion in 2025 and is projected to reach roughly $467 billion by 2030 (IQVIA Institute), making cancer treatment the single largest therapeutic category in pharmaceuticals. The competitive picture keeps shifting: Merck's Keytruda faces a 2028 patent cliff, BMS's Revlimid has already lost roughly half its sales to generics, and a wave of Chinese-originated antibody-drug conjugat...